Supplier News: Pace Life Sciences, Sartorius, ProBio, Sanner & More
The latest from CDMOs, CMOs, and suppliers featuring Pace Life Sciences, Sartorius, Acrinova, ProBio, Sanner, Nanotein Technologies.
Biologics Manufacturing
* ProBio Launches AAV Mfg Services
* Sartorius, Nanotein Technologies Partner for Cell Therapy Mfg
Formulation Development/Drug Product Manufacturing
* Pace Life Science Expands Aseptic Fill–Finish Facility
Appointments
* Acrinova Appoints Ex-Lonza Executive as New Managing Director
* Sanner Names New CEO
Biologics Manufacturing
ProBio Launches AAV Mfg Services
ProBio, a Pennington, New Jersey-based CDMO, has launched cGMP adeno-associated virus (AAV) manufacturing services at its facility in Hopewell, New Jersey. ProBio’s new capabilities include GMP plasmid DNA production, AAV vector manufacturing, and final drug product formulation and aseptic fill–finish.
Source: ProBio
Sartorius, Nanotein Technologies Partner for Cell Therapy Mfg
Sartorius Stedim Biotech and Nanotein Technologies, a developer of immune-cell activation reagents, have entered an agreement under which Sartorius will invest up to $3 million in a minority shareholding in Nanotein Technologies to support the commercialization and joint development of solutions based on Nanotein’s NanoSpark platform.
Under the agreement, Sartorius will offer Nanotein’s lead products to customers worldwide: the NanoSpark STEM-T Soluble T Cell Activator and NanoSpark GROW-NK Soluble Activator. These reagents are designed to enhance the expansion and quantity of T cells and natural killer (NK) cells, two key immune cell types used in a range of cell therapy applications, including CAR-T and NK-based cancer therapies.
In addition, Sartorius and Nanotein Technologies will collaborate using the NanoSpark platform to develop additional product offerings for cell and gene therapies.
Source: Sartorius
Formulation Development/Drug Product Manufacturing
Pace Life Science Expands Fill–Finish Facility
Pace Life Sciences, a contract, research, development and manufacturing organization and analytical testing laboratory, has re-opened its 33,000-square-foot facility in Salem, New Hampshire, a Center of Excellence for aseptic fill–finish, to support small-batch manufacturing.
The facility enhancements enable Pace Life Sciences to support clients requiring cGMP manufacturing with EU Annex 1 compliance in the injectable space for vaccines, gene therapies, antibodies, and protein-based therapeutics. The center offers capabilities in formulation development, analytical development, and sterile clinical supply manufacturing, and the ability to serve flexible batch sizes with manual fills and automated fills.
Source: Pace Life Sciences
Appointments
Acrinova Appoints Ex-Lonza, Siegfried Executive as New Managing Director
Arcinova, a newly launched CDMO and part of the UK-based CDMO Quotient Sciences, has appointed Christian Dowdeswell, formerly in executive roles with Lonza and Siegfried, as new Managing Director. He succeeds co-founder and Managing Director, Paul Ryan, who recently announced his retirement.
Dowdeswell joins Arcinova from consulting and advisory positions with companies, including Nanoform, a Helsinki, Finland-based company specializing in nanotechnology in drug delivery, and Pangaea Life Sciences, a technology and software company. Prior to this, he was Chief Business Officer, Drug Substances, Siegfried AG, and held various senior positions with Lonza, most recently as Vice President and Global Head of Commercial Development of Lonza’s small-molecules custom manufacturing business.
Over the past three to four years, under Quotient Sciences, the Arcinova facility in Alnwick, UK, has received £6.3 million ($7.3 million) investment to establish a 1,500-square-meter GMP manufacturing suite. The facility now houses 14 GMP manufacturing streams to enable the production of drug substances from small-scale process R&D batches to multi-kilo quantities to support projects from early development through to proof of concept. More recently, aseptic capabilities were enhanced to support the latest Annex 1 requirements.
Source: Arcinova
Sanner Names New CEO
Sanner, a provider of pharmaceutical packaging and drug delivery systems, has announced that Stefan Verheyden, currently Global Vice President, Sales Pharma and Biopharma Injectables at Gerresheimer, as the company’s CEO, effective in the fall 2025. The current CEO, Dr. Johannis Willem van Vliet, will leave the company shortly. Until the new CEO takes office in autumn 2025, Heino Lennartz, currently Chairman of Sanner, will take over as interim CEO and will be responsible for managing the company during the transition period and will support the future CEO during the handover.
Source: Sanner
